A Phase 3 interventional study of DMARD and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 53 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-26.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 19th largest by enrollment, is one of 5 that started in 2013, is one of 47 in phase 3, and was the 76th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 33rd largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2013, is one of 85 in phase 3, and was the 175th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label study will evaluate the efficacy and safety of subcutaneously administered RoActemra/Actemra (tocilizumab) as monotherapy or in combination with methotrexate or other non-biologic DMARDs in patients with active rheumatoid arthritis and an inadequate response to non-biologic DMARDs or to one anti-TNF. In Phase 1, all patients will receive RoActemra/Actemra 162 mg subcutaneously (sc) weekly for Weeks 1 to 24, with or without methotrexate or other non-biologic DMARDs. For Part 2, patients who achieve sustained clinical DAS28-ESR remission at Weeks 20 and 24 will be randomized to receive RoActemra/Actemra 162 mg sc either weekly or every 2 weeks for Weeks 24 to 48, with or without methotrexate or other non-biologic DMARDs. Patients who do not achieve sustained clinical remission but achieve low disease activity (DAS-ESR \</= 3.2) will continue the initial treatment of RoActemra/Actemra 162 mg sc weekly for Weeks 24 to 48, with or without methotrexate or other non-biologic DMARDs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DMARD · Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]
Drug: DMARD · Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]
Drug: DMARD · Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]
non-biological disease-modifying antirheumatic drugs at stable dose
stable dose
Drug page: Tocilizumab
162 mg subcutaneously (SC) qw, Weeks 1-24
Drug page: Tocilizumab
162 mg SC qw or q2w, Weeks 24-48
Drug page: Tocilizumab
162 mg SC qw, Weeks 24-48
Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.
Time frame: Week 20 and Week 24
Mean Change in Disease Activity Score 28 - Erythrocyte Sedimentation Rate(DAS28-ESR)
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.
Time frame: From week 24 up to week 48
Percentage of Patients Allocated in Groups A1 and A2 Who Remain With Clinical Remission Activity (DAS 28 ESR <2.6) up to Week 48
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.
Time frame: From week 28 up to week 48
Percentage of Patients Reporting Change in DAS 28 ESR >1.2 Until Week 48
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.
Time frame: From week 28 up to week 48
Percentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 24
The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).
Time frame: From week 2 until week 24
Percentage of Patients With American College of Rheumatology (ACR20, 50, 70, 90) Response Scores Until Week 48
The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).
Time frame: From week 28 until week 48
Number of Patients With Good and Moderate Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 24
DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.
Time frame: From week 2 until week 24
Number of Patients With Clinical Response According to European League Against Rheumatism (EULAR) Response Scores up to Week 48
DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.
Time frame: From week 28 until week 48
Mean Change in Clinical Disease Activity Index (CDAI) From Baseline up to Week 24
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Mean Change From Baseline in Clinical Disease Activity Index (CDAI) up to Week 48
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From week 24 until week 48
Mean Change in Simplified Disease Activity Index (SDAI) From Baseline up to Week 24
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
Time frame: From baseline to Week 24
Mean Change in Simplified Disease Activity Index (SDAI) From Week 24 up to Week 48
Simplified Disease Activity Index (SDAI) which is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
Time frame: From week 24 until week 48
Mean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 24
TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.
Time frame: From baseline to Week 24
Mean Change From Baseline in Total Tender Joint Counts (TJC) Until Week 48
TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.
Time frame: From week 24 until week 48
Mean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 24
SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.
Time frame: From baseline to Week 24
Mean Change in Total Swollen Joint Counts (SJC) From Baseline Until Week 48
SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.
Time frame: From week 24 until week 48
Percentages of Patients Who Achieve DAS28-ESR Remission (DAS28 < 2.6) up to Week 48
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.
Time frame: Week 48
Percentages of Patients With Remission (CDAI<2.8) Until Week 24
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Percentages of Patients With Remission (CDAI<2.8) Until Week 48
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From week 28 until week 48
Percentages of Patients With Remission (SDAI<3.3) Until Week 24
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
Time frame: From baseline to Week 24
Percentages of Patients With Remission (SDAI<3.3) Until Week 48
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
Time frame: From week 28 until week 48
Percentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 24
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR is used to calculate the DAS28 score.
Time frame: From baseline to Week 24
Percentage of Patients Who Achieve Low Disease Activity Based on DAS28-ESR Criteria (DAS28-ESR </=3.2) up to Week 48
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR was used to calculate the DAS28 score.
Time frame: From week 28 until week 48
Percentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 24
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Percentage of Patients Who Achieve Low Disease Activity Based on CDAI Score (CDAI<10) Until Week 48
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From week 28 until week 48
Percentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 24
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
Time frame: From baseline to Week 24
Percentage of Patients Who Achieved Low Disease Activity (LDA) Based on SDAI Score (SDAI<11) Until Week 48
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
Time frame: From week 28 until week 48
Safety: Number of Patients Reporting Adverse Events up to Week 24
Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 24
Time frame: From baseline to Week 24
Safety: Number of Patients Reporting Adverse Events up to Week 48
Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 48
Time frame: From week 24 until week 48
Immunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 24
Number of patients resulting positive to anti-tocilizumab antibodies test are reported.
Time frame: From baseline to Week 24
Immunogenicity: Number of Patients With Anti-tocilizumab Antibodies up to Week 48
Number of patients resulting positive to anti-tocilizumab antibodies test are reported.
Time frame: From week 24 until week 48
Immunogenicity: TCZ Levels up to Week 24
Mean concentrations of TCZ in patients' blood are reported.
Time frame: From baseline to Week 24
Immunogenicity: TCZ Levels at Week 36 and Early Withdrawal Visit
Mean concentrations of TCZ in patients' blood are reported.
Time frame: week 36 and early withdrawal visit
Immunogenicity: SIL-6R Levels up to Week 24
Mean concentration of SIL-6R in patients' blood are reported.
Time frame: From baseline to Week 24
Immunogenicity: SIL-6R Levels at Week 36 and Early Withdrawal Visit
Mean concentration of SIL-6R in patients' blood are reported.
Time frame: Baseline, Week 36 and Early Withdrawal Visit
Patient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 24
This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.
Time frame: From baseline to Week 24
Patient Global Assessment of Disease Activity Visual Analogue Scale (VAS) up to Week 48
This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.
Time frame: Baseline, from week 28 until week 48
Assessment of Pain Reported by the Patient (VAS) Until Week 24
This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".
Time frame: From baseline to Week 24
Assessment of Pain Reported by the Patient (VAS) Until Week 48
This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".
Time frame: Baseline, from week 28 until week 48
Health Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 24
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.
Time frame: From baseline to Week 24
Health Assessment Questionnaire-Disability Index (HAQ-DI) up to Week 48
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.
Time frame: Baseline, from week 28 until week 48
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 24
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.
Time frame: From baseline to Week 24
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) up to Week 48
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.
Time frame: Baseline, from week 28 until week 48
| Milestone | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|---|---|
| Started | 74 | 327 | 0 | 0 | 0 | 0 | 0 |
| Completed | 64 | 281 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 46 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 15 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Anaphylaxis or hypersensitivity reaction | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 9 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 89 | 90 | 95 | 67 | 2 |
| Completed | 0 | 0 | 84 | 89 | 89 | 59 | 0 |
| Not completed | 0 | 0 | 5 | 1 | 6 | 8 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 | 1 | 3 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24 | 48.4 (35.75 to 61.27) | 52.9 (46.83 to 58.83) |
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.
| mm/hr | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 24 | -4.07 ± 1.03 | -4.01 ± 1.13 |
| Week 28 | -3.94 ± 1.22 | -3.78 ± 1.31 |
| Week 32 | -3.97 ± 1.38 | -3.77 ± 1.17 |
| Week 36 | -3.82 ± 1.53 | -3.90 ± 1.16 |
| Week 40 | -3.95 ± 1.26 | -3.84 ± 1.19 |
| Week 44 | -4.05 ± 1.17 | -3.76 ± 1.17 |
| Week 48 | -4.14 ± 1.24 | -3.68 ± 1.32 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 88.5 (79.88 to 94.35) | 84.1 (74.75 to 91.02) |
| Week 32 | 87.2 (78.27 to 93.44) | 81.1 (71.49 to 88.59) |
| Week 36 | 80.2 (70.25 to 88.04) | 86.4 (77.39 to 92.75) |
| Week 40 | 82.1 (72.26 to 89.65) | 80.7 (70.88 to 88.32) |
| Week 44 | 89.0 (80.18 to 94.86) | 78.4 (68.35 to 86.47) |
| Week 48 | 91.5 (83.20 to 96.50) | 73.9 (63.41 to 82.66) |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR will be used to calculate the DAS28 score.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 96.6 (90.25 to 99.28) | 96.6 (90.36 to 99.29) |
| Week 32 | 96.5 (90.14 to 99.27) | 95.6 (89.01 to 98.78) |
| Week 36 | 93.0 (85.43 to 97.40) | 97.7 (92.03 to 99.72) |
| Week 40 | 98.8 (93.54 to 99.97) | 98.9 (93.83 to 99.97) |
| Week 44 | 98.8 (93.39 to 99.97) | 95.5 (88.77 to 98.75) |
| Week 48 | 100.0 (NA to NA) | 95.5 (88.77 to 98.75) |
The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| ACR20 - Week 2 | 27.0 (17.35 to 38.61) | 31.7 (26.59 to 37.08) |
| ACR20 - Week 4 | 50.7 (38.72 to 62.60) | 49.7 (44.00 to 55.37) |
| ACR20 - Week 8 | 67.1 (55.13 to 77.67) | 67.0 (61.36 to 72.30) |
| ACR20 - Week 12 | 80.0 (68.73 to 88.61) | 74.7 (69.31 to 79.52) |
| ACR20 - Week 16 | 79.7 (68.31 to 88.44) | 75.7 (70.35 to 80.49) |
| ACR20 - Week 20 | 73.8 (61.46 to 83.97) | 81.0 (75.93 to 85.38) |
| ACR20 - Week 24 | 79.7 (67.77 to 88.72) | 83.3 (78.39 to 87.44) |
| ACR20 - LOCF visit | 77.0 (67.77 to 88.72) | 79.0 (78.39 to 87.44) |
| ACR50 - week 2 | 9.5 (3.89 to 18.52) | 13.2 (9.66 to 17.38) |
| ACR50 - week 4 | 20.5 (11.98 to 31.62) | 25.3 (20.59 to 30.53) |
| ACR50 - week 8 | 37.0 (25.97 to 49.09) | 41.3 (35.70 to 47.14) |
| ACR50 - week 12 | 51.4 (39.17 to 63.56) | 52.7 (46.84 to 58.51) |
| ACR50 - week 16 | 53.6 (41.20 to 65.72) | 52.4 (46.50 to 58.25) |
| ACR50 - week 20 | 58.5 (45.56 to 70.56) | 58.5 (52.48 to 64.24) |
| ACR50 - week 24 | 59.4 (46.37 to 71.49) | 58.7 (52.72 to 64.53) |
| ACR50 - LOCF visit | 55.4 (46.37 to 71.49) | 54.2 (52.72 to 64.53) |
| ACR70 - week 2 | 5.4 (1.49 to 13.27) | 2.8 (1.30 to 5.29) |
| ACR70 - week 4 | 12.3 (5.80 to 22.12) | 10.6 (7.39 to 14.53) |
| ACR70 - week 8 | 17.8 (9.84 to 28.53) | 22.7 (18.05 to 27.83) |
| ACR70 - week 12 | 32.9 (22.09 to 45.12) | 27.0 (22.05 to 32.47) |
| ACR70 - week 16 | 29.0 (18.69 to 41.16) | 32.2 (26.87 to 37.88) |
| ACR70 - week 20 | 33.8 (22.57 to 46.65) | 36.6 (31.01 to 42.52) |
| ACR70 - week 24 | 40.6 (28.51 to 53.63) | 37.7 (32.03 to 43.67) |
| ACR70 - LOCF visit | 37.8 (28.51 to 53.63) | 33.9 (32.03 to 43.67) |
| ACR90 - week 2 | 1.4 (0.03 to 7.30) | 0.9 (0.19 to 2.72) |
| ACR90 - week 4 | 2.7 (0.33 to 9.55) | 1.6 (0.52 to 3.70) |
| ACR90 - week 8 | 6.8 (2.26 to 15.26) | 7.3 (4.65 to 10.89) |
| ACR90 - week 12 | 12.9 (6.05 to 23.01) | 8.8 (5.82 to 12.61) |
| ACR90 - week 16 | 13.0 (6.14 to 23.32) | 12.0 (8.49 to 16.27) |
| ACR90 - week 20 | 13.8 (6.53 to 24.66) | 13.7 (9.95 to 18.29) |
| ACR90 - week 24 | 23.4 (13.75 to 35.69) | 16.7 (12.56 to 21.61) |
| ACR90 - LOCF visit | 20.3 (13.75 to 35.69) | 15.0 (12.56 to 21.61) |
The definition of improvement of ACR core set of outcome measures includes an improvement equal or higher to the 20%, 50%, 70%, 90% compared to Baseline in both Swollen Joint Count (SJC) and Tender Joint Count (TJC) as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, patient's Global Assessment of disease activity VAS, patient's assessment of pain VAS, HAQ-DI, and acute phase reactant (either CRP or erythrocyte sedimentation rate \[ESR\]).
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| ACR20 - Week 28 | 90.0 (82.7 to 95.99) | 92.2 (84.63 to 96.82) |
| ACR20 - Week 32 | 93.1 (85.59 to 97.43) | 94.4 (87.51 to 98.17) |
| ACR20 - Week 36 | 84.9 (75.54 to 91.70) | 91.0 (83.05 to 96.04) |
| ACR20 - Week 40 | 88.1 (79.19 to 94.14) | 93.2 (85.75 to 97.46) |
| ACR20 - Week 44 | 91.5 (83.20 to 96.50) | 91.0 (83.05 to 96.04) |
| ACR20 - Week 48 | 96.4 (89.92 to 99.26) | 88.8 (80.31 to 94.48) |
| ACR20 - LOCF visit | 95.5 (88.89 to 98.76) | 87.8 (79.18 to 93.74) |
| ACR50 - Week 28 | 79.5 (69.61 to 87.40) | 81.1 (71.49 to 88.59) |
| ACR50 - Week 32 | 85.1 (75.80 to 91.80) | 83.3 (74.00 to 90.36) |
| ACR50 - Week 36 | 74.4 (63.87 to 83.22) | 83.1 (73.73 to 90.25) |
| ACR50 - Week 40 | 79.8 (69.59 to 87.75) | 81.8 (72.16 to 89.24) |
| ACR50 - Week 44 | 80.5 (70.26 to 88.42) | 78.7 (68.69 to 86.63) |
| ACR50 - Week 48 | 88.1 (79.19 to 94.14) | 79.8 (69.93 to 87.55) |
| ACR50 - LOCF visit | 84.3 (75.02 to 91.12) | 78.9 (69.01 to 86.79) |
| ACR70 - Week 28 | 59.1 (48.09 to 69.46) | 57.8 (46.91 to 68.12) |
| ACR70 - Week 32 | 65.5 (54.56 to 75.39) | 54.4 (43.60 to 64.98) |
| ACR70 - Week 36 | 61.6 (50.51 to 71.92) | 62.9 (52.03 to 72.93) |
| ACR70 - Week 40 | 65.5 (54.31 to 75.52) | 59.1 (48.09 to 69.46) |
| ACR70 - Week 44 | 67.1 (55.81 to 77.06) | 59.6 (48.62 to 69.83) |
| ACR70 - Week 48 | 71.4 (60.53 to 80.76) | 65.2 (54.33 to 74.96) |
| ACR70 - LOCF visit | 68.5 (57.83 to 77.97) | 64.4 (53.65 to 74.26) |
| ACR90 - Week 28 | 27.3 (18.32 to 37.81) | 32.2 (22.75 to 42.90) |
| ACR90 - Week 32 | 35.6 (25.65 to 46.62) | 31.1 (21.77 to 41.74) |
| ACR90 - Week 36 | 33.7 (23.88 to 44.72) | 30.3 (21.03 to 40.99) |
| ACR90 - Week 40 | 41.7 (31.00 to 52.94) | 29.5 (20.29 to 40.22) |
| ACR90 - Week 44 | 34.1 (24.03 to 45.45) | 27.0 (18.10 to 37.42) |
| ACR90 - Week 48 | 45.2 (34.34 to 56.48) | 32.6 (23.02 to 43.34) |
| ACR90 - LOCF visit | 42.7 (32.26 to 53.63) | 32.2 (22.75 to 42.90) |
DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.
| Number of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Good response - week 2 | 14 | 61 |
| Moderate response - week 2 | 36 | 196 |
| Good response - week 4 | 18 | 109 |
| Moderate response - week 4 | 49 | 175 |
| Good response - week 8 | 37 | 162 |
| Moderate response - week 8 | 32 | 121 |
| Good response - week 12 | 41 | 194 |
| Moderate response - week 12 | 27 | 95 |
| Good response - week 16 | 45 | 209 |
| Moderate response - week 16 | 22 | 76 |
| Good response - week 20 | 45 | 221 |
| Moderate response - week 20 | 18 | 56 |
| Good response - week 24 | 48 | 225 |
| Moderate response - week 24 | 16 | 53 |
| Good response - LOCF visit | 54 | 247 |
| Moderate response - LOCF visit | 19 | 73 |
DAS28-based EULAR response criteria were used to measure individual response as good or moderate depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to =\<1.2 with DAS28 ≤5.1.
| Number of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Good response - week 28 | 82 | 77 |
| Moderate response - week 28 | 5 | 10 |
| Good response - week 32 | 79 | 81 |
| Moderate response - week 32 | 6 | 9 |
| Good response - week 36 | 75 | 80 |
| Moderate response - week 36 | 9 | 8 |
| Good response - week 40 | 75 | 81 |
| Moderate response - week 40 | 9 | 7 |
| Good response - week 44 | 78 | 75 |
| Moderate response - week 44 | 4 | 13 |
| Good response - week 48 | 78 | 73 |
| Moderate response - week 48 | 4 | 15 |
| Good response - LOCF visit | 84 | 74 |
| Moderate response - LOCF visit | 5 | 16 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| CDAI score | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline values | 33.06 ± 12.45 | 32.06 ± 12.28 |
| Week 2 | -7.54 ± 9.57 | -8.62 ± 9.22 |
| Week 4 | -13.03 ± 10.91 | -13.23 ± 10.65 |
| Week 8 | -18.06 ± 11.05 | -18.46 ± 11.61 |
| Week 12 | -21.56 ± 11.77 | -20.60 ± 11.42 |
| Week 16 | -23.01 ± 12.33 | -21.79 ± 11.57 |
| Week 20 | -24.07 ± 11.97 | -22.88 ± 12.10 |
| Week 24 | -25.80 ± 13.31 | -23.43 ± 11.62 |
| LOCF visit | -24.42 ± 13.50 | -21.58 ± 12.85 |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| CDAI score | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline values | 29.27 ± 10.90 | 29.64 ± 12.13 |
| Week 24 | -25.54 ± 10.60 | -25.34 ± 12.10 |
| Week 28 | -24.75 ± 10.64 | -24.01 ± 12.30 |
| Week 32 | -24.56 ± 12.93 | -25.12 ± 11.64 |
| Week 36 | -23.90 ± 11.56 | -25.45 ± 11.42 |
| Week 40 | -25.16 ± 10.43 | -25.45 ± 11.75 |
| Week 44 | -25.45 ± 10.11 | -25.26 ± 11.75 |
| Week 48 | -26.44 ± 11.13 | -25.13 ± 12.51 |
| LOCF visit | -25.74 ± 11.29 | -24.87 ± 12.67 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
| SDAI score | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline values | 48.66 ± 31.48 | 44.40 ± 22.91 |
| Week 2 | -20.45 ± 19.01 | -19.50 ± 18.75 |
| Week 4 | -27.86 ± 23.54 | -24.34 ± 20.98 |
| Week 8 | -32.61 ± 26.84 | -29.34 ± 21.96 |
| Week 12 | -36.23 ± 27.04 | -30.95 ± 23.58 |
| Week 16 | -37.82 ± 31.09 | -32.66 ± 22.79 |
| Week 20 | -36.79 ± 25.47 | -33.95 ± 23.05 |
| Week 24 | -41.38 ± 31.51 | -34.80 ± 22.44 |
| LOCF visit | -39.15 ± 30.45 | -32.73 ± 22.84 |
Simplified Disease Activity Index (SDAI) which is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
| SDAI score | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline values | 41.45 ± 24.90 | 40.92 ± 21.42 |
| Week 24 | -37.02 ± 24.60 | -35.88 ± 20.71 |
| Week 28 | -35.15 ± 25.90 | -34.50 ± 20.66 |
| Week 32 | -35.60 ± 26.97 | -34.88 ± 20.53 |
| Week 36 | -35.29 ± 26.55 | -35.35 ± 20.07 |
| Week 40 | -37.26 ± 25.48 | -35.70 ± 19.80 |
| Week 44 | -37.09 ± 25.17 | -35.06 ± 21.77 |
| Week 48 | -37.93 ± 26.32 | -35.02 ± 21.74 |
| LOCF visit | -36.93 ± 25.75 | -34.69 ± 21.75 |
TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.
| TJC | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline visit | 18.05 ± 12.98 | 19.12 ± 13.38 |
| Week 2 | -4.31 ± 7.56 | -5.00 ± 8.06 |
| Week 4 | -7.04 ± 11.77 | -7.96 ± 9.43 |
| Week 8 | -9.81 ± 10.37 | -10.90 ± 11.10 |
| Week 12 | -12.27 ± 10.47 | -12.01 ± 10.88 |
| Week 16 | -13.43 ± 12.35 | -13.09 ± 11.02 |
| Week 20 | -13.65 ± 11.73 | -13.70 ± 11.48 |
| Week 24 | -15.47 ± 13.35 | -14.20 ± 11.46 |
| LOCF visit | -14.36 ± 12.87 | -13.19 ± 11.75 |
TCJ is a clinical assessment of 68 joints which are classified as tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints are not be taken into consideration.
| TJC | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline values | 15.42 ± 9.05 | 15.97 ± 12.77 |
| Week 28 | -13.66 ± 8.44 | -12.88 ± 11.52 |
| Week 32 | -13.40 ± 8.99 | -13.88 ± 11.43 |
| Week 36 | -13.13 ± 8.82 | -13.78 ± 11.70 |
| Week 40 | -14.06 ± 8.58 | -14.49 ± 12.07 |
| Week 44 | -14.32 ± 8.25 | -13.93 ± 11.62 |
| Week 48 | -14.40 ± 8.61 | -13.43 ± 12.17 |
| LOCF visit | -13.96 ± 8.68 | -13.27 ± 12.20 |
SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.
| SJC | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline values | 10.05 ± 7.99 | 9.76 ± 6.64 |
| Week 2 | -3.22 ± 4.40 | -3.42 ± 5.10 |
| Week 4 | -5.07 ± 5.58 | -5.46 ± 5.41 |
| Week 8 | -7.38 ± 6.47 | -6.81 ± 6.03 |
| Week 12 | -7.93 ± 7.13 | -7.60 ± 6.00 |
| Week 16 | -8.35 ± 7.71 | -8.01 ± 6.05 |
| Week 20 | -8.72 ± 7.56 | -8.37 ± 6.50 |
| Week 24 | -9.13 ± 7.66 | -8.38 ± 6.59 |
| LOCF visit | -8.47 ± 7.48 | -7.71 ± 6.67 |
SJC is a clinical assessment of 66 joints classified as swollen/not swollen by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints will not be taken into consideration for swelling.
| SJC | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline values | 9.28 ± 6.52 | 9.23 ± 7.55 |
| Week 28 | -8.64 ± 6.19 | -8.14 ± 6.81 |
| Week 32 | -8.54 ± 7.02 | -8.62 ± 7.13 |
| Week 36 | -8.48 ± 6.50 | -8.38 ± 6.76 |
| Week 40 | -8.85 ± 6.40 | -8.51 ± 6.59 |
| Week 44 | -8.73 ± 6.62 | -8.62 ± 6.97 |
| Week 48 | -9.06 ± 6.58 | -8.72 ± 7.34 |
| LOCF visit | -8.82 ± 6.51 | -8.64 ± 7.33 |
The DAS 28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP) and general health status. For this study ESR was used to calculate the DAS 28 score.
| Percentage of participants | Phase 2 Arm A1 - Monotherapy - qw | Phase 2 Arm A1- Combination Therapy - qw | Phase 2 Arm A2 - Monotherapy - q2w | Phase 2 Arm A2 - Combination Therapy - q2w |
|---|---|---|---|---|
| Week 28 | 82.6 (61.22 to 95.05) | 90.6 (80.70 to 96.48) | 87.0 (66.41 to 97.22) | 83.1 (71.73 to 91.24) |
| Week 32 | 81.8 (59.72 to 94.81) | 89.1 (78.75 to 95.49) | 78.3 (56.30 to 92.54) | 82.1 (70.80 to 90.39) |
| Week 36 | 90.5 (69.62 to 98.83) | 76.9 (64.81 to 86.47) | 86.4 (65.09 to 97.09) | 86.4 (75.69 to 93.57) |
| Week 40 | 85.0 (62.11 to 96.79) | 81.3 (69.54 to 89.92) | 77.3 (54.63 to 92.18) | 81.8 (70.39 to 90.24) |
| Week 44 | 94.7 (73.97 to 99.87) | 87.3 (76.50 to 94.35) | 77.3 (54.63 to 92.18) | 78.8 (66.98 to 87.89) |
| Week 48 | 100 (NA to NA) | 89.1 (78.75 to 95.49) | 77.3 (54.63 to 92.18) | 72.7 (60.36 to 82.97) |
| LOCF Visit | 91.3 (71.96 to 98.93) | 89.4 (79.36 to 95.63) | 73.9 (51.59 to 89.77) | 73.1 (60.90 to 83.24) |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline visit | 0 (0 to 0) | 0 (0 to 0) |
| Week 2 | 2.7 (0.33 to 9.42) | 1.6 (0.51 to 3.62) |
| Week 4 | 2.7 (0.33 to 9.55) | 5.1 (2.96 to 8.19) |
| Week 8 | 11.0 (4.85 to 20.46) | 14.4 (10.61 to 18.88) |
| Week 12 | 15.7 (8.11 to 26.38) | 19.3 (14.92 to 24.22) |
| Week 16 | 18.8 (10.43 to 30.06) | 22.8 (18.06 to 28.02) |
| Week 20 | 27.7 (17.31 to 40.19) | 26.8 (21.70 to 32.31) |
| Week 24 | 29.7 (18.91 to 42.42) | 30.2 (24.93 to 35.99) |
| LOCF visit | 29.7 (19.66 to 41.48) | 29.4 (24.48 to 34.62) |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 46.6 (35.88 to 57.54) | 48.3 (37.59 to 59.16) |
| Week 32 | 48.3 (37.42 to 59.25) | 45.6 (35.02 to 56.40) |
| Week 36 | 52.3 (41.27 to 63.21) | 46.6 (35.88 to 57.54) |
| Week 40 | 52.4 (41.19 to 63.40) | 45.5 (34.80 to 56.42) |
| Week 44 | 50.0 (38.75 to 61.25) | 50.6 (39.75 to 61.33) |
| Week 48 | 59.0 (47.69 to 69.72) | 53.9 (43.04 to 64.56) |
| LOCF Visit | 57.8 (46.91 to 68.12) | 60.3 (52.77 to 67.56) |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline visit | 0 (0 to 0) | 0 (0 to 0) |
| Week 2 | 1.4 (0.04 to 7.50) | 1.9 (0.71 to 4.14) |
| Week 4 | 2.9 (0.35 to 9.94) | 4.8 (2.72 to 7.83) |
| Week 8 | 11.1 (4.92 to 20.72) | 14.6 (10.75 to 19.13) |
| Week 12 | 14.3 (7.07 to 24.71) | 18.8 (14.47 to 23.72) |
| Week 16 | 17.4 (9.32 to 28.41) | 22.2 (17.56 to 27.47) |
| Week 20 | 28.1 (17.60 to 40.76) | 25.8 (20.77 to 31.36) |
| Week 24 | 31.7 (20.58 to 44.69) | 28.8 (23.53 to 34.49) |
| LOCF visit | 28.4 (18.50 to 40.05) | 25.4 (20.75 to 30.46) |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 50.0 (39.02 to 60.98) | 46.0 (35.23 to 57.00) |
| Week 32 | 48.8 (37.90 to 59.86) | 45.6 (35.02 to 56.40) |
| Week 36 | 53.5 (42.41 to 64.32) | 47.7 (36.96 to 58.65) |
| Week 40 | 55.4 (44.10 to 66.34) | 44.3 (33.73 to 55.30) |
| Week 44 | 50.0 (38.75 to 61.25) | 47.2 (36.51 to 58.06) |
| Week 48 | 52.4 (41.11 to 63.59) | 47.7 (36.96 to 58.65) |
| LOCF Visit | 51.7 (40.48 to 62.41) | 47.8 (37.13 to 58.57) |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR is used to calculate the DAS28 score.
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Week 2 | 21.6 (12.89 to 32.72) | 21.5 (17.12 to 26.47) |
| Week 4 | 26.0 (16.45 to 37.62) | 36.8 (31.39 to 42.41) |
| Week 8 | 50.7 (38.72 to 62.60) | 55.4 (49.54 to 61.16) |
| Week 12 | 58.6 (46.17 to 70.23) | 67.7 (62.01 to 73.00) |
| Week 16 | 66.7 (54.29 to 77.56) | 72.4 (66.89 to 77.48) |
| Week 20 | 67.7 (54.95 to 78.77) | 78.2 (72.91 to 82.83) |
| Week 24 | 75.0 (62.60 to 84.98) | 81.1 (75.98 to 85.49) |
| LOCF visit | 73.0 (61.39 to 82.65) | 74.0 (68.90 to 78.68) |
The DAS28 is a combined index for measuring disease activity in RA. The index includes the assessment of 28 joints for swelling and tenderness, acute phase response (ESR or CRP), and general health status. For this study ESR was used to calculate the DAS28 score.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 95.4 (88.64 to 98.73) | 88.6 (80.09 to 94.41) |
| Week 32 | 91.9 (83.95 to 96.66) | 92.2 (84.63 to 96.82) |
| Week 36 | 87.2 (78.27 to 93.44) | 92.0 (84.30 to 96.74) |
| Week 40 | 89.3 (80.63 to 94.98) | 92.0 (84.30 to 96.74) |
| Week 44 | 96.3 (89.68 to 99.24) | 87.5 (78.73 to 93.59) |
| Week 48 | 95.1 (87.98 to 98.66) | 86.4 (77.39 to 92.75) |
| LOCF Visit | 94.4 (87.37 to 98.15) | 85.6 (76.57 to 92.08) |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Week 2 | 13.5 (6.68 to 23.45) | 16.9 (12.98 to 21.50) |
| Week 4 | 24.7 (15.32 to 36.14) | 26.9 (22.08 to 32.21) |
| Week 8 | 41.1 (29.71 to 53.23) | 47.5 (41.71 to 53.32) |
| Week 12 | 57.1 (44.75 to 68.91) | 52.4 (46.51 to 58.17) |
| Week 16 | 62.3 (49.83 to 73.71) | 60.7 (54.81 to 66.35) |
| Week 20 | 66.2 (53.35 to 77.43) | 65.1 (59.29 to 70.68) |
| Week 24 | 71.9 (59.24 to 82.40) | 66.9 (61.07 to 72.38) |
| LOCF visit | 66.2 (54.28 to 76.81) | 61.2 (55.64 to 66.48) |
Clinical Disease Activity Index (CDAI) is an index for measuring disease activity in rheumatoid arthritis (RA). The index was calculated using the following formula: CDAI = number of swollen joints using the 28-joint count (SJC28) + number of tender joints using the 28-joint count (TJC28) + patient global assessment of disease (PGA) based on 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) based on 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 0 (no disease activity) to 10 (maximum disease activity). Total CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 86.4 (77.39 to 92.75) | 85.4 (76.32 to 91.99) |
| Week 32 | 89.7 (81.27 to 95.16) | 86.7 (77.87 to 92.92) |
| Week 36 | 80.2 (70.25 to 88.04) | 89.8 (81.47 to 95.22) |
| Week 40 | 86.9 (77.78 to 93.28) | 88.6 (80.09 to 94.41) |
| Week 44 | 89.0 (80.18 to 94.86) | 85.4 (76.32 to 91.99) |
| Week 48 | 92.8 (84.93 to 97.30) | 87.6 (78.96 to 93.67) |
| LOCF Visit | 91.0 (83.05 to 96.04) | 87.8 (79.18 to 93.74) |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
| Percentage of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Week 2 | 16.7 (8.92 to 27.30) | 17.6 (13.56 to 22.32) |
| Week 4 | 27.1 (17.20 to 39.10) | 28.3 (23.36 to 33.65) |
| Week 8 | 41.7 (30.15 to 53.89) | 48.1 (42.31 to 54.00) |
| Week 12 | 58.6 (46.17 to 70.23) | 55.6 (49.74 to 61.41) |
| Week 16 | 63.8 (51.31 to 75.01) | 62.5 (56.63 to 68.11) |
| Week 20 | 65.6 (52.70 to 77.05) | 66.3 (60.43 to 71.83) |
| Week 24 | 74.6 (62.06 to 84.73) | 67.3 (61.41 to 72.75) |
| LOCF visit | 63.5 (51.51 to 74.40) | 56.9 (51.32 to 62.32) |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity.
| Percentage of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Week 28 | 84.9 (75.54 to 91.70) | 83.89 (74.48 to 90.91) |
| Week 32 | 89.5 (81.06 to 95.10) | 85.6 (76.57 to 92.08) |
| Week 36 | 79.1 (68.95 to 87.10) | 87.5 (78.73 to 93.59) |
| Week 40 | 86.7 (77.52 to 93.19) | 86.4 (77.39 to 92.75) |
| Week 44 | 91.5 (83.20 to 96.50) | 82.0 (72.45 to 89.36) |
| Week 48 | 93.9 (86.34 to 97.99) | 81.8 (72.16 to 89.24) |
| LOCF Visit | 91.0 (83.05 to 96.04) | 81.1 (71.49 to 88.59) |
Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 24
| Number of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Any treatment emergent adverse event (TEAE) | 52 | 254 |
| At least one TEAE of special interest | 2 | 13 |
| At least one serious TEAE | 3 | 10 |
| At least one TEAE leading to dose modification | 24 | 103 |
| At least one TEAE leading to discontinuation | 4 | 21 |
Number of patients reporting any treatment emergent adverse event (TEAE), at least one TEAE of special interest, at least one serious TEAE, at least one TEAE leading to dose modification, at least one TEAE leading to discontinuation up to week 48
| Number of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|
| Any TEAE | 50 | 63 | 68 | 46 | 1 |
| At least one TEAE of special interest | 1 | 2 | 2 | 4 | 0 |
| At least one serious TEAE | 2 | 1 | 2 | 5 | 1 |
| At least one TEAE leading to dose modification | 15 | 23 | 23 | 21 | 1 |
| At least one TEAE leading to discontinuation | 0 | 0 | 0 | 2 | 0 |
Number of patients resulting positive to anti-tocilizumab antibodies test are reported.
| Number of participants | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Screen - Baseline | 6 | 13 |
| Screen - Week 12 | 1 | 2 |
| Screen - Week 24 | 3 | 9 |
| Confirmatory - Baseline | 4 | 5 |
| Confirmatory - Week 12 | 1 | 0 |
| Confirmatory - Week 24 | 1 | 3 |
Number of patients resulting positive to anti-tocilizumab antibodies test are reported.
| Number of participants | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|
| Screen - Week 36 | 0 | 0 | 0 | 2 | — |
| Screen - Week 48 | 1 | 3 | 2 | 3 | — |
| Confirmatory - Week 36 | 0 | 0 | 0 | 1 | — |
| Confirmatory - Week 48 | 0 | 0 | 0 | 1 | — |
Mean concentrations of TCZ in patients' blood are reported.
| mcg/ml | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline | 0.49 ± NA | 0.67 ± 0.34 |
| Week 12 | 37.97 ± 20.11 | 41.23 ± 20.89 |
| Week 24 | 46.42 ± 28.35 | 46.87 ± 27.65 |
Mean concentrations of TCZ in patients' blood are reported.
| mcg/ml | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|
| Week 36 | 48.47 ± 30.17 | 16.77 ± 16.10 | 41.89 ± 28.82 | 48.33 ± 25.79 | — |
| Early withdrawal visit | 36.45 ± 18.03 | 19.20 ± NA | 24.43 ± 20.83 | 13.75 ± 4.60 | 1.78 ± NA |
Mean concentration of SIL-6R in patients' blood are reported.
| mcg/ml | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline | 42.85 ± 16.26 | 39.29 ± 11.10 |
| Week 12 | 566.47 ± 210.49 | 570.34 ± 228.54 |
| Week 24 | 570.49 ± 198.26 | 565.34 ± 198.32 |
Mean concentration of SIL-6R in patients' blood are reported.
| mcg/ml | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|
| Baseline | 39.87 ± 10.46 | 39.70 ± 16.46 | 39.39 ± 11.24 | 43.11 ± 11.85 | 37.30 ± 11.46 |
| Week 36 | 539.89 ± 152.71 | 476.28 ± 156.50 | 542.99 ± 168.30 | 552.65 ± 184.21 | — |
| Early withdrawal visit | 412.53 ± 323.49 | 643.00 ± NA | 338.38 ± 230.82 | 217.74 ± 236.21 | 513.00 ± NA |
This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.
| Millimeters | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline | 65.26 ± 19.77 | 59.40 ± 17.61 |
| Week 2 | 49.53 ± 22.78 | 44.16 ± 21.97 |
| Week 4 | 38.21 ± 22.92 | 35.19 ± 20.83 |
| Week 8 | 30.03 ± 21.65 | 26.04 ± 20.59 |
| Week 12 | 22.71 ± 18.56 | 22.24 ± 17.97 |
| Week 16 | 19.28 ± 18.22 | 20.71 ± 18.65 |
| Week 20 | 16.80 ± 16.68 | 18.79 ± 17.79 |
| Week 24 | 16.63 ± 15.19 | 19.00 ± 18.36 |
| LOCF visit | 20.36 ± 19.25 | 22.23 ± 20.86 |
This patient reported outcome assessment represents the patient's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). The line was marked by the participant and the distance from the left edge was recorded and the mean values are reported.
| Millimeters | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline | 58.97 ± 17.40 | 60.96 ± 20.13 |
| Week 28 | 11.97 ± 14.10 | 12.74 ± 15.07 |
| Week 32 | 10.78 ± 15.33 | 10.80 ± 11.36 |
| Week 36 | 11.99 ± 16.23 | 10.30 ± 13.20 |
| Week 40 | 10.62 ± 13.49 | 10.94 ± 14.12 |
| Week 44 | 9.50 ± 11.30 | 10.06 ± 12.14 |
| Week 48 | 8.13 ± 10.52 | 9.99 ± 13.88 |
| LOCF visit | 8.97 ± 11.63 | 10.21 ± 13.96 |
This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".
| Millimeters | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline | 66.38 ± 20.70 | 58.59 ± 23.70 |
| Week 2 | 53.20 ± 24.43 | 47.46 ± 25.14 |
| Week 4 | 43.11 ± 24.69 | 42.88 ± 24.57 |
| Week 8 | 35.95 ± 24.62 | 34.28 ± 25.94 |
| Week 12 | 29.44 ± 22.37 | 31.07 ± 24.97 |
| Week 16 | 32.17 ± 22.01 | 30.18 ± 24.00 |
| Week 20 | 26.58 ± 22.13 | 28.26 ± 24.16 |
| Week 24 | 23.56 ± 21.17 | 26.43 ± 23.30 |
| LOCF visit | 27.34 ± 24.41 | 29.78 ± 25.18 |
This patient reported outcome assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain".
| Millimeters | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline | 55.73 ± 21.68 | 56.00 ± 23.56 |
| Week 28 | 17.33 ± 20.14 | 15.67 ± 17.65 |
| Week 32 | 17.08 ± 20.47 | 17.27 ± 17.69 |
| Week 36 | 18.81 ± 23.88 | 14.36 ± 15.65 |
| Week 40 | 16.96 ± 20.89 | 17.07 ± 17.86 |
| Week 44 | 15.05 ± 18.02 | 16.27 ± 17.70 |
| Week 48 | 11.90 ± 15.56 | 16.31 ± 19.85 |
| LOCF visit | 12.74 ± 15.99 | 16.41 ± 19.76 |
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.
| HAQ-DI score | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline | 1.49 ± 0.76 | 1.36 ± 0.70 |
| Week 2 | 1.39 ± 0.74 | 1.18 ± 0.69 |
| Week 4 | 1.20 ± 0.74 | 1.05 ± 0.69 |
| Week 8 | 1.10 ± 0.75 | 0.95 ± 0.71 |
| Week 12 | 0.99 ± 0.74 | 0.91 ± 0.71 |
| Week 16 | 0.99 ± 0.72 | 0.87 ± 0.70 |
| Week 20 | 0.88 ± 0.70 | 0.83 ± 0.71 |
| Week 24 | 0.85 ± 0.71 | 0.82 ± 0.70 |
| LOCF visit | 0.97 ± 0.76 | 0.88 ± 0.73 |
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.
| HAQ-DI score | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline | 1.21 ± 0.68 | 1.20 ± 0.70 |
| Week 28 | 0.58 ± 0.56 | 0.57 ± 0.64 |
| Week 32 | 0.55 ± 0.58 | 0.57 ± 0.63 |
| Week 36 | 0.60 ± 0.60 | 0.56 ± 0.64 |
| Week 40 | 0.55 ± 0.56 | 0.61 ± 0.67 |
| Week 44 | 0.53 ± 0.57 | 0.58 ± 0.66 |
| Week 48 | 0.53 ± 0.61 | 0.57 ± 0.66 |
| LOCF visit | 0.55 ± 0.61 | 0.56 ± 0.66 |
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.
| FACIT-F score | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy |
|---|---|---|
| Baseline | 81.72 ± 24.75 | 89.16 ± 24.49 |
| Week 2 | 86.64 ± 25.00 | 95.82 ± 25.42 |
| Week 4 | 92.26 ± 25.30 | 99.54 ± 27.15 |
| Week 8 | 96.45 ± 25.88 | 103.46 ± 27.25 |
| Week 12 | 98.29 ± 25.47 | 104.08 ± 26.79 |
| Week 16 | 98.41 ± 27.08 | 105.51 ± 26.94 |
| Week 20 | 102.46 ± 27.24 | 104.91 ± 27.47 |
| Week 24 | 104.36 ± 27.16 | 107.01 ± 27.60 |
| LOCF visit | 101.38 ± 28.24 | 104.65 ± 28.07 |
The symptom-specific measure FACIT-F assesses chronic illness therapy with special emphasis on fatigue in the past 7 days and consists of 5 dimensions: 1) physical well- being, 2) social/family well-being, 3) emotional well-being, 4) functional well-being, and 5) additional concerns. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much for a total possible FACIT-F score of 0 to 160. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions.
| FACIT-F score | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) |
|---|---|---|
| Baseline | 17.36 ± 5.16 | 17.13 ± 5.67 |
| Week 28 | 23.50 ± 3.82 | 23.12 ± 4.47 |
| Week 32 | 23.62 ± 4.16 | 22.98 ± 4.86 |
| Week 36 | 23.23 ± 4.21 | 22.90 ± 4.64 |
| Week 40 | 23.39 ± 4.40 | 23.02 ± 4.38 |
| Week 44 | 23.48 ± 4.21 | 23.13 ± 4.45 |
| Week 48 | 23.95 ± 3.79 | 22.87 ± 4.87 |
| LOCF visit | 23.69 ± 4.07 | 22.88 ± 4.85 |
Collected over After initiation of study drug, all AEs, regardless of relationship to study drug, are reported until study closure.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Tocilizumab Monotherapy | 0/74 (0%) | 3/74 (4.1%) | 24/74 (32.4%) |
| Phase 1: Combination Therapy | 1/327 (0.3%) | 10/327 (3.1%) | 119/327 (36.4%) |
| Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | 0/89 (0%) | 2/89 (2.2%) | 17/89 (19.1%) |
| Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | 0/90 (0%) | 1/90 (1.1%) | 25/90 (27.8%) |
| Phase 2 Arm B: Participants With Low Disease Activity | 0/95 (0%) | 2/95 (2.1%) | 30/95 (31.6%) |
| Phase 2 Arm C: Moderate EULAR Response at Week 24 | 2/67 (3%) | 5/67 (7.5%) | 23/67 (34.3%) |
| Phase 2 Arm D: Non Responders | 0/2 (0%) | 1/2 (50%) | 0/2 (0%) |
| Event | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|---|---|
| AscitesGastrointestinal disorders | 0/74 | 0/327 | 0/89 | 0/90 | 0/95 | 0/67 | 1/2 |
| Coronary artery diseaseCardiac disorders | 0/74 | 0/327 | 0/89 | 0/90 | 0/95 | 1/67 | 0/2 |
| Myocardial infarctionCardiac disorders | 0/74 | 0/327 | 0/89 | 0/90 | 0/95 | 1/67 | 0/2 |
| Spinal fractureInjury, poisoning and procedural complications | 0/74 | 0/327 | 0/89 | 0/90 | 0/95 | 1/67 | 0/2 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/74 | 0/327 | 0/89 | 0/90 | 0/95 | 1/67 | 0/2 |
| Hypertensive crisisVascular disorders | 0/74 | 0/327 | 0/89 | 0/90 | 0/95 | 1/67 | 0/2 |
| PericarditisCardiac disorders | 1/74 | 0/327 | 0/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| HeadacheNervous system disorders | 1/74 | 0/327 | 0/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| Deep vein thrombosisVascular disorders | 1/74 | 0/327 | 0/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| IleusGastrointestinal disorders | 0/74 | 0/327 | 1/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| Event | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy | Phase 2 Arm A1: TCZ +/- nbDMARD Once Per Week (qw) | Phase 2 Arm A2: TCZ +/- nbDMARD Every Two Weeks (q2w) | Phase 2 Arm B: Participants With Low Disease Activity | Phase 2 Arm C: Moderate EULAR Response at Week 24 | Phase 2 Arm D: Non Responders |
|---|---|---|---|---|---|---|---|
| Transaminases increasedInvestigations | 1/74 | 37/327 | 0/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| Upper respiratory tract infectionInfections and infestations | 2/74 | 23/327 | 9/89 | 7/90 | 3/95 | 4/67 | 0/2 |
| Urinary tract infectionInfections and infestations | 6/74 | 23/327 | 3/89 | 2/90 | 8/95 | 3/67 | 0/2 |
| Injection site erythemaGeneral disorders | 6/74 | 10/327 | 0/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/74 | 0/327 | 2/89 | 3/90 | 6/95 | 3/67 | 0/2 |
| Oedema peripheralGeneral disorders | 0/74 | 0/327 | 0/89 | 1/90 | 3/95 | 4/67 | 0/2 |
| NasopharyngitisInfections and infestations | 0/74 | 0/327 | 2/89 | 4/90 | 5/95 | 4/67 | 0/2 |
| HeadacheNervous system disorders | 0/74 | 0/327 | 2/89 | 1/90 | 0/95 | 4/67 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 4/74 | 18/327 | 1/89 | 5/90 | 3/95 | 2/67 | 0/2 |
| NauseaGastrointestinal disorders | 1/74 | 18/327 | 0/89 | 0/90 | 0/95 | 0/67 | 0/2 |
| Age, Continuous(years) | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy | Total |
|---|---|---|---|
| Mean | 53.5 ± 12.7 | 53.6 ± 12.2 | 53.6 ± 12.3 |
| Sex: Female, Male(Participants) | Phase 1: Tocilizumab Monotherapy | Phase 1: Combination Therapy | Total |
|---|---|---|---|
| Female | 62 | 264 | 326 |
| Male | 12 | 63 | 75 |
The record gives a start of Sep 2013, a primary completion of Jul 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Tocilizumab